product name Ipratropium Bromide
Description: Ipratropium Bromide is an antagonist of M3 type muscarinic acetylcholine receptors, used for the treatment of chronic obstructive pulmonary disease (COPD). Ipratropium bromide combined with Formoterol partially protects the lungs against the chronic inflammation and airspace enlargement by reducing neutrophilic infiltration possibly via the inhibition of MMP-9 activity. Ipratropium bromide (1 nM) significantly increases [Ca(2+)](i), decreases forward scatter and increases annexin-V-binding. Ipratropium bromide treatment is followed by slight but significant increase of hemolysis.
References: Eur J Pharmacol. 2010 Nov 25;647(1-3):178-87; Equine Vet J. 1999 Jan;31(1):20-4.
412.37
Formula
C20H30BrNO3
CAS No.
22254-24-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 83 mg/mL (201.3 mM)
Water: 83 mg/mL (201.3 mM)
Ethanol: 83 mg/mL (201.3 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19390872
| In Vitro |
In vitro activity: Ipratropium bromide combined with Formoterol partially protects the lungs against the chronic inflammation and airspace enlargement by reducing neutrophilic infiltration possibly via the inhibition of MMP-9 activity. Ipratropium bromide (1 nM) significantly increases [Ca(2+)](i), decreases forward scatter and increases annexin-V-binding. Ipratropium bromide treatment is followed by slight but significant increase of hemolysis. Ipratropium bromide triggers suicidal erythrocyte death or eryptosis, an effect mainly due to stimulation of Ca(2+)-entry. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Ipratropium dry powder inhalation (DPI) at a dose of 2400 mg/horse is an effective bronchodilator in these horses at rest but it has little effect on the airway calibre during the recovery period. Ipratropium significantly attenuates the lung lesions associated with parenchyma inflammatory cell influx and congestion observed in the cadmium treated rats. Ipratropium bromide partially protects the lungs against the inflammation by reducing neutrophilic infiltration. Ipratropium is an antagonist for pre-junctional muscarinic inhibitory receptors on pulmonary parasympathetic nerves and also confirms its potent antagonist actions on post-junctional muscarinic receptors in the airway smooth muscle in the guinea-pig. Ipratropium decreases the maximal change in pleural pressure during tidal breathing (delta Pplmax) and pulmonary resistance (RL) and increases dynamic compliance (Cdyn) in horse. |
| Animal model | |
| Formulation & Dosage | |
| References | Eur J Pharmacol. 2010 Nov 25;647(1-3):178-87; Equine Vet J. 1999 Jan;31(1):20-4. |
Related Posts
product name Ipratropium Bromide
Description: Ipratropium Bromide is an antagonist of M3 type muscarinic acetylcholine receptors, used for the treatment of chronic obstructive pulmonary disease (COPD). Ipratropium bromide combined with Formoterol partially protects the lungs against the chronic inflammation and airspace enlargement by reducing neutrophilic infiltration possibly via the inhibition of MMP-9 activity. Ipratropium bromide (1 nM) significantly increases [Ca(2+)](i), decreases forward scatter and increases annexin-V-binding. Ipratropium bromide treatment is followed by slight but significant increase of hemolysis.
References: Eur J Pharmacol. 2010 Nov 25;647(1-3):178-87; Equine Vet J. 1999 Jan;31(1):20-4.
412.37
Formula
C20H30BrNO3
CAS No.
22254-24-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 83 mg/mL (201.3 mM)
Water: 83 mg/mL (201.3 mM)
Ethanol: 83 mg/mL (201.3 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19390872
| In Vitro |
In vitro activity: Ipratropium bromide combined with Formoterol partially protects the lungs against the chronic inflammation and airspace enlargement by reducing neutrophilic infiltration possibly via the inhibition of MMP-9 activity. Ipratropium bromide (1 nM) significantly increases [Ca(2+)](i), decreases forward scatter and increases annexin-V-binding. Ipratropium bromide treatment is followed by slight but significant increase of hemolysis. Ipratropium bromide triggers suicidal erythrocyte death or eryptosis, an effect mainly due to stimulation of Ca(2+)-entry. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Ipratropium dry powder inhalation (DPI) at a dose of 2400 mg/horse is an effective bronchodilator in these horses at rest but it has little effect on the airway calibre during the recovery period. Ipratropium significantly attenuates the lung lesions associated with parenchyma inflammatory cell influx and congestion observed in the cadmium treated rats. Ipratropium bromide partially protects the lungs against the inflammation by reducing neutrophilic infiltration. Ipratropium is an antagonist for pre-junctional muscarinic inhibitory receptors on pulmonary parasympathetic nerves and also confirms its potent antagonist actions on post-junctional muscarinic receptors in the airway smooth muscle in the guinea-pig. Ipratropium decreases the maximal change in pleural pressure during tidal breathing (delta Pplmax) and pulmonary resistance (RL) and increases dynamic compliance (Cdyn) in horse. |
| Animal model | |
| Formulation & Dosage | |
| References | Eur J Pharmacol. 2010 Nov 25;647(1-3):178-87; Equine Vet J. 1999 Jan;31(1):20-4. |